Biocom Responds to Section 232 Pharmaceutical Tariffs

Got story updates? Submit your updates here. ›

Biocom, a major life sciences industry association representing companies across California, has issued a statement expressing concerns over potential new tariffs on pharmaceutical imports under Section 232 of the Trade Expansion Act. The group argues that such tariffs could disrupt the supply chain and increase drug prices for consumers.

Why it matters

The proposed tariffs are part of a broader push by the federal government to address high drug prices in the U.S. However, Biocom contends that tariffs are the wrong approach and could have unintended negative consequences for the life sciences industry and patients.

The details

Biocom's statement argues that tariffs on imported pharmaceuticals would lead to higher costs for drug manufacturers, which would then be passed on to consumers in the form of higher prices. The group also warns that supply chain disruptions could limit access to critical medicines. Biocom represents over 1,400 life sciences companies, research organizations, and service providers across California.

• The proposed tariffs were announced by the federal government in April 2026.

What’s next

Biocom plans to continue advocating against the proposed pharmaceutical tariffs and work with policymakers to find alternative solutions to address drug pricing.